BAAR, Switzerland — Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Academy of Allergy and Clinical Immunology (EAACI) congress, taking place from June 12 to 15 in Istanbul, Turkey. The company will host a scientific symposium entitled “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission.” Three leading international experts will explore how landmark breakthroughs in immunology have deepened our understanding of immune tolerance, presenting
emerging data on remission and long-term outcomes in respiratory allergy. Together, these insights reinforce AIT’s disease-modifying potential and its growing role in personalised medicine. “EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field. Stallergenes Greer is proud contribute to these conversations, bringing together world-leading experts in pursuit of scientific progress and meaningfully better outcomes for patients,” said Dr Silvia Scurati, Chief Medical Officer, Stallergenes Greer. Strong scientific presence at EAACI 2026 Stallergenes Greer’s will feature 23
abstracts at the congress, including two oral presentations and nine flash talks, reflecting the company’s sustained commitment to generating clinically meaningful, long-term evidence and research with the potential to redefine the treatment of respiratory allergy. Key highlights include: Debut data from YOBI, the paediatric phase III study of 300 IR Birch liquid sublingual immunotherapy (SLIT) New real-world evidence from VORAN, evaluating the 300 IR House Dust Mite (HDM) SLIT tablet Updated findings from EfficAPSI, the largest real-world longitudinal cohort study of SLIT to date SYMPOSIUM
PROGRAMME COMPANY SPONSORED SYMPOSIUM (June 12, 13:30–14:30 – Room: Utrecht, Level B2) “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission” Chair: Prof. Mübeccel Akdiş, Switzerland – “Turning off allergy at its source: The potential of AIT” Speaker: Prof. Mübeccel Akdiş, Switzerland – “Birch SLIT: What’s New in the Evidence?” Speaker: Prof. Oliver Pfaar, Germany – “From consensus to clinical impact: AIT outcomes through the lens of remission” Speaker: Prof. J. Christian Virchow, Germany ABOUT STALLERGENES GREER STUDIES EfficAPSI and
YOBI EfficAPSI1,2,3 is the largest retrospective real-world, longitudinal cohort study regarding SLIT treatment to date. The study evaluated the real-life impact of SLIT-liquid on asthma onset and progression in patients with allergic rhinitis, drawing on data from more than 110,000 patients treated with Stallergenes Greer’s SLIT-liquid and symptomatic drugs, alongside a comparator cohort of more than 330,000 patients receiving symptomatic treatment alone, all with allergic rhinitis, with or without asthma, in France between January 2010 to December 2018. YOBI4 is a phase IIIb clinical study
evaluating the safety and efficacy of 300IR Birch SLIT-liquid in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC). The trial enrolled 553 children aged 5-17 years across 64 sites in 12 European countries. Participants received a daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. YOBI met its primary endpoint, demonstrating a statistically significant and clinically meaningful 41% improvement in the ARC total combined score during the second pollen season versus placebo (p
Stallergenes Greer, EAACI 2026, allergen immunotherapy, AIT, long-term outcomes, remission, YOBI, EfficAPSI, VORAN, SLIT, birch SLIT, house dust mite SLIT, personalised medicine